Related references
Note: Only part of the references are listed.Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
Ulrich Jaeger et al.
BLOOD REVIEWS (2020)
Cold agglutinin disease revisited: a multinational, observational study of 232 patients
Sigbjorn Berentsen et al.
BLOOD (2020)
Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program
Georg Gelbenegger et al.
BLOOD ADVANCES (2020)
Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis
Catherine M. Broome et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis
Gerard Socie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Mortality Among Patients with Cold Agglutinin Disease in the United States: An Electronic Health Record (EHR)-Based Analysis
Quentin A. Hill et al.
BLOOD (2019)
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial
Ulrich Jaeger et al.
BLOOD (2019)
Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease
Lauren C. Bylsma et al.
BLOOD ADVANCES (2019)
Novel insights into the treatment of complement-mediated hemolytic anemias
Sigbjorn Berentsen et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Cold agglutinin disease: current challenges and future prospects
Sigbjorn Berentsen et al.
JOURNAL OF BLOOD MEDICINE (2019)
A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway
Johann Bartko et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action
Douglas Sheridan et al.
PLOS ONE (2018)
Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease
Sigbjorn Berentsen
SEMINARS IN HEMATOLOGY (2018)
Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial
Alexander Roeth et al.
BLOOD ADVANCES (2018)
Cytokine signature associated with disease severity in chronic fatigue syndrome patients
Jose G. Montoya et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial
Sigbjorn Berentsen et al.
BLOOD (2017)
Minimal important differences for fatigue patient reported outcome measures-a systematic review
Asa Nordin et al.
BMC MEDICAL RESEARCH METHODOLOGY (2016)
Uncoupling complement C1s activation from C1q binding in apoptotic cell phagocytosis and immunosuppressive capacity
Lucrezia Colonna et al.
CLINICAL IMMUNOLOGY (2016)
Cold agglutinin disease
Sigbjorn Berentsen
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS
Roxanne Cofiell et al.
BLOOD (2015)
Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia
Sigbjorn Berentsen et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2015)
TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins
Ju Shi et al.
BLOOD (2014)
Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma
Ulla Randen et al.
HAEMATOLOGICA (2014)
Treatment of autoimmune hemolytic anemias
Alberto Zanella et al.
HAEMATOLOGICA (2014)
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome
M. Cugno et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
C1-inhibitor efficiently inhibits Escherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood
A. Landsem et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation
Ilene C. Weitz et al.
THROMBOSIS RESEARCH (2012)
Validation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale in Patients with Moderately to Severely Active Systemic Lupus Erythematosus, Participating in a Clinical Trial
Jin-Shei Lai et al.
JOURNAL OF RHEUMATOLOGY (2011)
High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease
Sigbjorn Berentsen et al.
BLOOD (2010)
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
Robert A. Brodsky et al.
BLOOD (2008)
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients
S Berentsen et al.
BLOOD (2004)
Complement activation in a model of chronic fatigue syndrome
B Sorensen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2003)
Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales
D Cella et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2002)
Share Paper
